Advancements in Sustainable Pharma and Investment Trends for Quaker Chemical Corp

Green Chemistry

The 2024 Peter J. Dunn Award and CMO Excellence in Green Chemistry Award honor leaders in sustainable pharmaceutical manufacturing. This year’s recipients—Boehringer Ingelheim, GSK, and PharmaBlock—have made significant contributions to advancing environmental sustainability in industrial practices.

Boehringer Ingelheim’s Efficient Synthesis: Boehringer Ingelheim developed a groundbreaking three-step synthesis for Spiroketone CD 7659, boosting yield nearly five-fold and reducing solvent usage by an astonishing 99%. This innovative process has the potential for waste savings exceeding 69 million kilograms.

GSK’s Sustainable Cancer Drug Production: GSK has implemented a new manufacturing route for maleimidocaproyl monomethyl auristatin F (MMAF), cutting solvent consumption by 16,160 kg per kilogram of product and reducing greenhouse gas emissions by 71%. This achievement highlights the transformative power of green chemistry in the pharmaceutical sector.

PharmaBlock’s Micro-packed Bed Technology: PharmaBlock, based in Nanjing, China, received the CMO Excellence Award for its micro-packed bed technology, promoting eco-friendly pharmaceutical production.

 Insights from these projects were shared during a webinar moderated by John Tucker, underscoring green chemistry’s critical role in sustainable active pharmaceutical ingredient (API) development.

Investments

Quaker Chemical Corp. is attracting institutional investor interest, with 77.46% of its stock held by institutional investors. Despite Deutsche Bank lowering its price target from $225 to $190, the buy rating remains. Recent activities include a 17.6% stake increaseby Inspire Investing LLC in Q3 and a doubling of holdings by GAMMA Investing LLC, along with new positions by Fidelis Capital Partners and First Pacific Financial. Mather Group LLC and Fifth Third Bancorp also raised their investments, reflecting growing investor confidence.